Akebia Therapeutics, Inc.
Every calculator, already run for AKBA
Open the full toolkit →You have the numbers on AKBA. Get the argument.
A written report on which of these readings actually decide the outcome for Akebia Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
6 analysts covering AKBAAnalyst Price Target Disagreement for Akebia Therapeutics, Inc.
Wall Street's bull case implies +572% from the current price; the bear case implies +12%. A 560% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for AKBA
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acut…
AKBA — frequently asked
Is AKBA a buy right now?
Wall Street's consensus rating on Akebia Therapeutics, Inc. is Strong Buy across 6 analysts, with a mean price target of $3.92 (+339% vs. the current $0.89). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is AKBA overvalued?
AKBA trades at — trailing earnings, against a DCF fair value of $5 per share. The current price implies -10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is AKBA's next earnings date?
Akebia Therapeutics, Inc. is next scheduled to report earnings around Nov 9, 2026. A full AKBA research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Akebia Therapeutics, Inc.?
Analysts covering Akebia Therapeutics, Inc. (AKBA) range from a bear-case target of $1.00 to a bull-case high of $6.00, with a mean consensus target of $3.92 across 6 analysts. The spread of $5.00 (560% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Akebia Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Akebia Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full AKBA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Akebia Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.